Rosiglitazone depresses activation of rat hepatic stellate cells in vitro

GUO Yan-tong,ZHAO Jing-ming,SONG Lei,ZHOU Mai,JIAO Gang-jun,LI Tao,LENG Xi-sheng
DOI: https://doi.org/10.3969/j.issn.1001-6325.2008.11.003
2008-01-01
Abstract:Objective To investigate the mechanism of effect of rosiglitazone(PPARγ ligand) on rat hepatic stellate cells(HSCs) in vitro.Methods The primary cultured HSCs were randomly divided into three groups:the control group,TGF-β1(5 μg/L)group,group of TGF-β1 plus 10 μmol/L rosiglitazone.Detecting the samples 48 hours after the HSCs were treated with TGF-β1(5 ng/mL)and TGF-β1 with 10 μmol/L rosiglitazone respectively:The expression of type Ⅰ pro-collagen was detected by reverse-transcription polymerase chain reaction(RT-PCR).The expressions of SMAD3、SMAD4、SMAD7、α-smooth muscle actin(α-SMA) and type Ⅰcollagen were measured by Western blot assays.α-SMA was marked by immunofluorescence and observed through confocal microscope.The cell proliferation was determined with MTT colorimetric assay.Results TGF-β1 significantly increased the proliferation of HSCs and thus promoted HSCs to express type Ⅰcollagen and α-SMA(P<0.01);these effects of TGF-β1 were suppressed by rosiglitazone(P<0.01).The difference of expression of SMAD3、SMAD4、SMAD7 in each group was not statistically significant.Conclusion PPARγ ligand can suppress the activation of TGF-β1 on HSCs.
What problem does this paper attempt to address?